• IDEX’s third-quarter 2026 diluted EPS rose 15% year over year to $1.95, primarily due to improved operational results.
• Net sales increased 8% to $951.7 million, driven by higher volumes, primarily in Health & Science Technologies, and positive pricing.
• Orders climbed 13% to $991.2 million, while operating cash flow rose 18% to $239.5 million.
• Chief Executive Eric D. Ashleman said momentum was broadening across the portfolio beyond advantaged markets and larger acquired businesses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEX Corporation published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.